Ralexar Therapeutics company is developing topical and systemic therapies based on the Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis.Alexar changes its name toRalexar Therapeutics. The company was founded in 2013 and is based in Malvern, Pennsylvania.

Biotechnology

Clinical Trials

Therapeutics

Ralexar Therapeutics

Ralexar Therapeutics' headquarters in Malvern, PA, United States

Description

People

Jobs